PolyMedix develops biomimetics - novel small molecule drugs which mimic the activity of proteins. These are designed with a proprietary computational technology platform. We focus on a specific field of biology with many potential product opportunities: membrane proteins and protein:protein interactions. PolyMedix has identified two drug programs for clinical trials in 2007: a novel antibiotic drug, and a heparin antagonist.

PolyMedix has raised over $30 million since being founded in 2002, including a $21 million financing and public offering in February 2006, and three approved SBIR grants (including a $3 million Advanced Technology grant). PolyMedix is a publicly traded company (OTC BB:PYMX), having completed a reverse merger public offering in February 2006.

See PolyMedix quote at Yahoo! finance

return to top ^